ERBB receptors and cancer: the complexity of targeted inhibitors.
Citations
6,441 citations
4,705 citations
4,185 citations
3,056 citations
3,040 citations
Cites background from "ERBB receptors and cancer: the comp..."
...Ligand occupancy of the EGFR activates the RAS/ RAF/MAPK, STAT, and PI3K/AKT signaling pathways, which together modulate cellular proliferation, adhesion, angiogenesis, migration, and survival.(5,6) The anti-EGFR targeted antibodies cetuximab and panitumumab administered as monotherapy in CRC have shown response and disease stabilization rates of approximately 10% and 30%, respectively....
[...]
References
28,811 citations
"ERBB receptors and cancer: the comp..." refers background in this paper
...Resistance to ERBB-directed therapeutics During the process of cancer development, cells acquire multiple mutations, each of which contribute to and are necessary for full malignancy (reviewed in Ref...
[...]
11,597 citations
10,879 citations
"ERBB receptors and cancer: the comp..." refers background in this paper
...Somatic mutations in the tyrosine-kinase domain of EGFR were recently identified in non-small-cell lung cancers (NSCLCs) in a subgroup of patients that showed clinical responses to treatment with the TKIs gefitini...
[...]
10,532 citations
9,265 citations